Arginine Replacement Therapy in COVID-19
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- Emory University
- Study ID
- NCT05855330
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 3 Years - 21 Years
- Healthy Volunteers
- Not accepted
Interventions
- Arginine Hydrochloride — DRUGArginine will be infused based on the manufacturer's instructions (R-Gene 10, Pfizer), over 30 minutes. However, rates may be slowed to over 60 minutes for patients experiencing symptoms of flushing, nausea, vomiting, or headache at the research team's discretion. Pediatric doses will be drawn up by the pharmacy.
Study Details
This study aims to investigate if receiving doses of arginine (a protein in the body) will improve mitochondria function in children with COVID-19. The study will be performed at the Children's Healthcare of Atlanta, Arthur M. Blank Hospital. Patients will be randomized to receive one of three doses of arginine three times a day for five days or at discharge whichever comes first.
Key Dates
- Start date
- Jan 8, 2024
- Status verified
- Apr 2026
- Primary completion
- Jun 30, 2028
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 21 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: L-arginine loading dose + standard doseL-arginine loading dose (200 mg/kg IV) + standard dose (100 mg/kg IV TID).
- Active Comparator: Standard doseStandard dose (100mg/kg IV TID).
- Active Comparator: Low doseLow dose (25mg/kg IV TID).
Primary Outcome Measure
Change in mitochondrial function [ Time Frame: Baseline and day 5 ]
Central Contacts
- Claudia R. Morris, MD404 727-5500
- Dunia Hatabah, MD470-6626706
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's Healthcare of Atlanta (CHOA), Arthur M. Blank | Atlanta | Georgia | 30322 | Caludia R Morris, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Atlanta, GA
By condition
By specialty
Related Studies
- Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q SystemEnrolling By Invitation · Emory University · Atlanta, Georgia
- EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseasePHASE3 · Recruiting · Pfizer · Phoenix, Arizona
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVIDPHASE3 · Recruiting · Wes Ely · Tucson, Arizona
- A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing FormulationsPHASE4 · Recruiting · ModernaTX, Inc. · Atlanta, Georgia